Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
18 déc. 2024 08h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by...
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
17 déc. 2024 08h00 HE
|
Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
27 nov. 2024 08h00 HE
|
Immuneering Corporation
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
13 nov. 2024 16h05 HE
|
Immuneering Corporation
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
11 nov. 2024 08h00 HE
|
Autonomix Medical, Inc.
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6...
Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction
31 oct. 2024 08h00 HE
|
Autonomix Medical, Inc.
79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure Company reaches 60% enrollment with 15 patients1 successfully enrolled; No unexpected...
ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS
28 oct. 2024 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that...
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
15 oct. 2024 08h00 HE
|
Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Molecular Oncology Market Size is projected to Reach USD 7.4 billion, Garnering an 11.0% by 2034: Transparency Market Research Inc.
11 oct. 2024 08h41 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The global molecular oncology market (분자종양학 시장) was projected to attain US$ 2.3 billion in...
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress
09 oct. 2024 07h07 HE
|
Panavance Therapeutics Inc.
Misetionamide-gemcitabine combination demonstrates very good safety profile and potential therapeutic benefit in the challenging treatment of pancreatic adenocarcinoma Interim results show ~40% of...